CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Xenon Pharmaceuticals Inc.

XENE
$5.11B
Mid Cap
NASDAQPharmaceutical Preparations🇺🇸North AmericaBURNABY316 employees

Drugs in Pipeline

6

Phase 3 Programs

2

Upcoming Catalysts

5

Next Catalyst

Aug 10, 2026

12d

Market Overview

Stock performance and key metrics

XENE News
Catalyst Timeline

5 upcoming, 0 past

EarningsNext

XENE Earnings Report

Aug 10, 2026

EPS Est: $-1.16 | FQ end 2026-06

4 more catalysts beyond 14 days

Start a 48-hour free trial to see all upcoming catalysts

Pro

How XENE's past catalysts played out

Drug Pipeline
Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in Xenon Pharmaceuticals Inc.'s drug pipeline?

CatalystAlert tracks 6 drug candidates in Xenon Pharmaceuticals Inc.'s (XENE) pipeline across Phase 3, Phase 2. Its lead program is XEN1101 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Xenon Pharmaceuticals Inc.'s next FDA catalyst?

Xenon Pharmaceuticals Inc.'s (XENE) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track XENE biotech catalysts?

Add XENE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xenon Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply